Home
 Search
 Category
 Compounds
 Status
 Download
 Contacts
 Resources


Compound category: Carboxylic acids and derivatives
(total 141 related compounds in database, current show from 121 to 130)
 
Compound name 2D structure Target pathogen(s) Related VF/VFcategory Max phase Reference(s)
N'-[(E)-(5-bromo-2-hydroxyphenyl)methylideneamino]oxamide Depiction based on curated SMILES H 2 N O O NH N Br OH Salmonella
Shigella		 TTSS (SPI-1 encode); TTSS (SPI-2 encode)
TTSS (Type III secretion system)		 Preclinical (in vitro)
Preclinical (in vitro)		 Negrea A, et al. 2007. Antimicrob Agents Chemother
Veenendaal AK, et al. 2009. J Bacteriol
(E)-N'-(3,5-Dibromo-2-hydroxybenzylidene)nicotinohydrazide Depiction based on curated SMILES N OH Br O Br N N H Chlamydia
Escherichia
Salmonella		 TTSS (Type III secretion system)
TTSS (Type III secretion system)
TTSS (SPI-1 encode); TTSS (SPI-2 encode)		 Preclinical (in vitro)
Preclinical (in vitro)
Preclinical (in vitro)		 Bailey L, et al. 2007. FEBS Lett
Tree JJ, et al. 2009. Infect Immun; Wang D, et al. 2011. J Biol Chem
Negrea A, et al. 2007. Antimicrob Agents Chemother
Nicotinic acid (5-bromo-2-hydroxy-benzylidene)-hydrazide Depiction based on curated SMILES N OH O Br N N H Salmonella
Shigella		 TTSS (SPI-1 encode); TTSS (SPI-2 encode)
TTSS (Type III secretion system)		 Preclinical (in vitro)
Preclinical (in vitro)		 Negrea A, et al. 2007. Antimicrob Agents Chemother
Veenendaal AK, et al. 2009. J Bacteriol
CCG-38543
(internal name in literature)		 Depiction based on curated SMILES N H CH 3 OH H N O H CH 3 O OH N H O H Shigella VirF Preclinical (in vitro) Hurt JK, et al. 2010. J Biomol Screen
[(2R)-6-azaniumyl-1-[3-[3-[[(2R)-2,6-bis(azaniumyl)hexanoyl]amino]propyl-hexadecanoylamino]propylamino]-1-oxohexan-2-yl]azanium Depiction based on curated SMILES + N H H H N H O H H + N H H H + N H H H CH 3 O N N H O H + N H H Staphylococcus Biofilm Preclinical (in vitro) Konai MM, et al. 2015. ACS Infect Dis
[(2R)-6-azaniumyl-1-[3-[3-[[(2R)-2,6-bis(azaniumyl)hexanoyl]amino]propyl-tetradecanoylamino]propylamino]-1-oxohexan-2-yl]azanium Depiction based on curated SMILES + N H H H HN O H + N H H H + N H H H O H 3 C N HN O H + N H H H Staphylococcus Biofilm Preclinical (in vitro) Konai MM, et al. 2015. ACS Infect Dis
[(2S)-6-azaniumyl-1-[3-[3-[[(2S)-2,6-bis(azaniumyl)hexanoyl]amino]propyl-decanoylamino]propylamino]-1-oxohexan-2-yl]azanium Depiction based on curated SMILES H + N H H H N H O + N H H H + N H H H O N CH 3 N H O H + N H H H Staphylococcus Biofilm Preclinical (in vitro) Konai MM, et al. 2015. ACS Infect Dis
[(2S)-6-azaniumyl-1-[3-[3-[[(2S)-2,6-bis(azaniumyl)hexanoyl]amino]propyl-dodecanoylamino]propylamino]-1-oxohexan-2-yl]azanium Depiction based on curated SMILES H + N H H H N H O + N H H H + N H H H O N CH 3 N H O H + N H H H Staphylococcus Biofilm Preclinical (in vitro) Konai MM, et al. 2015. ACS Infect Dis
[(2S)-6-azaniumyl-1-[3-[3-[[(2S)-2,6-bis(azaniumyl)hexanoyl]amino]propyl-hexadecanoylamino]propylamino]-1-oxohexan-2-yl]azanium Depiction based on curated SMILES + N H H H N H O H H + N H H H + N H H H CH 3 O N N H O H + N H H Staphylococcus Biofilm Preclinical (in vitro) Konai MM, et al. 2015. ACS Infect Dis
[(2S)-6-azaniumyl-1-[3-[3-[[(2S)-2,6-bis(azaniumyl)hexanoyl]amino]propyl-octadecanoylamino]propylamino]-1-oxohexan-2-yl]azanium Depiction based on curated SMILES O + N H H H + N H H H N H H + N H H H + N H H H CH 3 O N N H O H Staphylococcus Biofilm Preclinical (in vitro) Konai MM, et al. 2015. ACS Infect Dis
   


NOTE: for more interactive and statistic charts, please visit the JavaScript-rich interface of VFDB.



Page 1  ...  3  4  5  6  7  8  9  10  11  12  13  14  15 



Back to top
2004-2025 NIPB, CAMS&PUMC